PET Imaging of Differentiated Thyroid Cancer with TSHR-Targeted [ 89 Zr]Zr-TR1402
Molecular Pharmaceutics · 2024
DOI: 10.1021/acs.molpharmaceut.4c00224 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2024. Verfasst von Grayson R Gimblet und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, University of Alabama at Birmingham, Birmingham, Alabama 35294, United States. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Zirconium, Positron-Emission Tomography, Receptors, Thyrotropin. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: NCI NIH HHS, National Cancer Institute, Education and Research Foundation for Nuclear Medicine and Molecular Imaging.
Abstract (Originalsprache)
Thyroid cancer is the most common endocrine cancer, with differentiated thyroid cancers (DTCs) accounting for 95% of diagnoses. While most DTC patients are diagnosed and treated with radioiodine (RAI), up to 20% of DTC patients become RAI refractory (RAI-R). RAI-R patients have significantly reduced survival rates compared to patients who remain RAI-avid. This study explores [89Zr]Zr-TR1402 as a thyroid-stimulating hormone receptor (TSHR)-targeted PET radiopharmaceutical for DTC. [89Zr]Zr-TR1402 was synthesized with a molar activity of 25.9 MBq/nmol by conjugating recombinant human TSH (rhTSH) analogue TR1402 to chelator p-SCN-Bn-deferoxamine (DFO) in a molar ratio of 3:1 (DFO/TR1402) and radiolabeling with 89Zr (t1/2 = 78.4 h, β+ = 22.7%). As TSHR is absent in commonly available DTC-derived cell lines, TSHR was reintroduced via stable transduction by delivering a lentivirus containing the full-length coding region of the human TSHR gene. Receptor-mediated uptake of [89Zr]Zr-TR1402 was evaluated in vitro in stably transduced TSHR+ and wild-type TSHR- DTC cell lines. In vivo PET imaging was performed on Days 1-3 postinjection in male and female athymic nude mice bearing TSHR+ and TSHR- xenografts, along with ex vivo biodistribution on Day 3 postinjection. In vitro uptake of 1 nM [89Zr]Zr-TR1402 was significantly higher in TSHR+ THJ529T (P < 0.0001) and FTC133 (P < 0.01) cells than in TSHR- THJ529T and FTC133 cells. This uptake was shown to be specific in both TSHR+ THJ529T (P < 0.0001) and TSHR+ FTC133 (P < 0.0001) cells by blocking uptake with 250 nm DFO-TR1402. In vivo PET imaging showed accumulation of [89Zr]Zr-TR1402 in TSHR+ tumors, which was the highest on Day 1. In the male FTC133 xenograft model, ex vivo biodistribution confirmed a significant difference (P < 0.001) in uptake between FTC133+ (1.3 ± 0.1%ID/g) and FTC133- (0.8 ± 0.1%ID/g) tumors. A significant difference (P < 0.05) in uptake was also seen in the male THJ529T xenograft model between THJ529T+ (1.8 ± 0.6%ID/g) and THJ529T- (0.8 ± 0.4%ID/g) tumors. The in vitro and in vivo accumulation of [89Zr]Zr-TR1402 in TSHR-expressing DTC cell lines support the continued preclinical optimization of this approach.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, University of Alabama at Birmingham, Birmingham, Alabama 35294, United States.
- Department of Surgery, University of Alabama at Birmingham, Birmingham, Alabama 35294, United States.
- Department of Cancer Biology, Mayo Clinic Jacksonville, Jacksonville, Florida 32224, United States.
- Division of Hematology, Mayo Clinic Rochester, Rochester, Minnesota 55905, United States.
- Trophogen, Inc., Rockville, Maryland 20850, United States.
ORCID-Profile: Grayson R Gimblet
Förderung
- NCI NIH HHS
- National Cancer Institute
- Education and Research Foundation for Nuclear Medicine and Molecular Imaging
- University of Alabama at Birmingham
Zitieren
APA
Gimblet, G. R., Houson, H. A., Whitt, J., Reddy, P., Copland, J. A., Kenderian, S. S., Szkudlinski, M. W., Jaskula-Sztul, R., & Lapi, S. E. (2024). PET Imaging of Differentiated Thyroid Cancer with TSHR-Targeted [ 89 Zr]Zr-TR1402. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.4c00224
Vancouver
Gimblet GR, Houson HA, Whitt J, Reddy P, Copland JA, Kenderian SS, et al. PET Imaging of Differentiated Thyroid Cancer with TSHR-Targeted [ 89 Zr]Zr-TR1402. Molecular Pharmaceutics. 2024. doi:10.1021/acs.molpharmaceut.4c00224
BibTeX
@article{Gimblet2024,
author = {Gimblet, Grayson R and Houson, Hailey A and Whitt, Jason and Reddy, Pratheek and Copland, John Al and Kenderian, Saad S and Szkudlinski, Mariusz W and Jaskula-Sztul, Renata and Lapi, Suzanne E},
title = {PET Imaging of Differentiated Thyroid Cancer with TSHR-Targeted [ 89 Zr]Zr-TR1402},
journal = {Molecular Pharmaceutics},
year = {2024},
doi = {10.1021/acs.molpharmaceut.4c00224}
}
EUVIMED